Helicobacter pylori infection is associated with a spectrum of gastroduodenal diseases. The eradication of H. pylori has been recommended for most of the H. pylori associated diseases, particularly for peptic ulcer disease.
INTRODUCTION
Helicobacter pylori infection is associated with a spectrum of gastroduodenal diseases. The eradication of H. pylori has been recommended for most of the H. pylori associated diseases, particularly for peptic ulcer disease. 1±3 However, the ideal regimen for the treatment of H. pylori infection has not yet been established. Because no single agent provides acceptable rates of cure, combination regimens are presently required for the treatment of H. pylori infection. The classical bismuthbased triple therapy, which employs a combination of tripotassium dicitrato bismuthate (also called colloidal bismuth subcitrate), tetracycline (or amoxycillin) and SUMMARY Background: When metronidazole is used in bismuthbased or proton pump inhibitor-based triple therapy, the cure rate of Helicobacter pylori is usually high. However, metronidazole-resistant H. pylori strains, which are increasing in frequency, are a major cause of failed H. pylori eradication. Aim: To evaluate the ef®cacy of non-metronidazole containing bismuth-based triple therapy for H. pylori infection. Methods: One-hundred and eighty H. pylori-positive patients with endoscopically documented peptic ulcer disease or functional dyspepsia were randomly assigned to one of three 1-week regimens containing tripotassium dicitrato bismuthate (also called colloidal bismuth subcitrate H. pylori status was assessed by rapid urease test, histology and culture of gastric biopsy specimens taken from both the antrum and corpus, both before and at least 4 weeks after completion of therapy. Results: Thirteen patients dropped out (3 in group A, 5 in group B and 5 in group C). Based on an intention-totreat analysis, the eradication rates achieved in groups A, B and C were 88% (53/60), 58% (35/60) and 77% (46/60), respectively. These differences were signi®cant between groups A and B (P < 0.001), as well as between groups B and C (P < 0.05). Side-effects occurred in 7 (12%) patients in group A, 3 (5%) in group B and 8 (13%) in group C, and were mild, with the exception of vomiting in one patient (group C) that resulted in withdrawal from the study. Conclusion: One-week triple therapy, consisting of tripotassium dicitrato bismuthate, low-dose furazolidone and low-dose clarithromycin, achieves a high cure rate of H. pylori. metronidazole is considered a standard regimen for the treatment of H. pylori infection. 3±5 Eradication rates are high if the H. pylori strains are sensitive to metronidazole. However, metronidazole resistance is becoming an increasing problem world-wide, which will limit the usefulness of metronidazole-containing regimens.
6±9
This concern has prompted the search for effective, inexpensive, non-metronidazole therapies. 10 Furazolidone has been found to be highly effective in eradicating H. pylori, 11±14 with in-vitro studies suggesting a relatively low risk of developing resistance. 15 Clarithromycin is an important component of successful triple therapies for the treatment of H. pylori infection. Josamycin, another macrolide that has been in clinical use for many years, has not been extensively evaluated so far.
In the present study we used tripotassium dicitrato bismuthate-containing triple therapy regimens and furazolidone, clarithromycin, amoxycillin or josamycin, in order to evaluate the ef®cacy of these non-metronidazole regimens.
MATERIALS AND METHODS

Patients and endoscopy
The patients were recruited from the endoscopy suites at the Shanghai Institute of Digestive Diseases, First Af®liated Hospital of Sun Yat Sen University of Medical Science, Shanghai First Textile Bureau Worker's Hospital in the People's Republic of China, where they were undergoing evaluation for clinical symptoms and subsequently diagnosed with either duodenal ulcer or functional dyspepsia. Only patients with H. pylori infection were candidates for entry into the study. Informed consent was obtained from all patients. Patients who were pregnant, who had major organic or systemic diseases, had undergone previous gastric surgery, or who had received antibiotic therapy or proton pump inhibitors in the preceding 4 weeks were excluded. Endoscopy was performed within 3 days prior to treatment and again 4 weeks following the completion of treatment.
Assessment of H. pylori status
In each endoscopy, a total of eight biopsy specimens were taken, four from the antrum and four from the corpus. From each region, one biopsy was used for rapid urease testing, one for culture and two for histology (by haematoxylin & eosin stain). A diagnosis of H. pylori infection was based upon positive culture and/or positive histology in addition to a positive rapid urease test. Eradication of H. pylori was de®ned as all tests being negative at least 4 weeks after the completion of triple therapy.
Treatment
Patients included in the study randomly received one of the 1-week triple therapy regimens (listed in Table 1 ). All medicines were taken after meals. The treatment was open, but the microbiologists and pathologists were blinded with regard to the treatment arms. During the 7-day treatment period, the patients kept a diary in which to monitor compliance and symptoms.
Statistical analysis
Both intention-to-treat and per protocol analyses were used to express the eradication rates of H. pylori in all groups. Eradication rates, duodenal ulcer healing rates and frequencies of adverse events were compared using the v 2 test. The signi®cance level was set at P < 0.05.
RESULTS
One-hundred and eighty patients were included in this study, with 60 patients assigned to each of the three groups. Thirteen patients (3 in group A, 5 in group B and 5 in group C) dropped out, mainly because they refused a second endoscopy. One patient in group C was withdrawn from the study because of vomiting. One-hundred and sixty-six patients completed a course of treatment and follow-up endoscopy. Relevant demographic and endoscopic data at entrance to the study are given in Table 2 .
H. pylori eradication rates
H. pylori eradication rates are given in Table 3 . There were signi®cant differences in the eradication rates between groups A and B (P < 0.001), and between groups B and C (P < 0.05), both on the basis of intention-to-treat and per protocol analyses.
Duodenal ulcer healing rates
The healing rates of the active duodenal ulcer in each of the treatment groups are provided in Table 4 . There were no signi®cant differences in healing rates between the treatment groups (P > 0.05).
Side-effects
Side-effects associated with the treatment regimens are given in Table 6 . Eighteen of 180 patients (10.0%) reported mild side-effects which were tolerable and promptly disappeared after the cessation of medications. One patient was withdrawn from treatment because of excessive vomiting. There were no signi®cant differences in the rates of side-effects between all treatment groups (P > 0.05).
DISCUSSION
Classical bismuth-based triple therapy for H. pylori remains standard in many parts of world. This regimen typically requires a 2-week treatment course, which increases the risk of side-effects, as well as reducing patient compliance. Furthermore, a world-wide increase in H. pylori resistance to metronidazole, a key component of this triple therapy, limits the usefulness of this regimen. 6±9 Therefore, evaluations of new non-metronidazole bismuth-based triple therapies are warranted.
Furazolidone, a nitrofuran in clinical use for over 30 years, was used in China for the treatment of peptic ulcer disease long before H. pylori was discovered as an aetiological agent. 16, 17 In the last decade, furazolidone has been found to be highly effective for H. pylori eradication.
11±14 H. pylori resistance to furazolidone has not been encountered, and the serial passage of H. pylori did not result in development of resistance to furazolidone, suggesting that it is very unlikely that resistance will emerge easily. 15 Clarithromycin, a new generation macrolide, is highly effective for eradication of H. pylori, when it is included as a component of standard triple A combination of clarithromycin with amoxycillin in proton pump inhibitor-based triple therapies is effective, but insuf®ciently tested in a bismuth-based triple therapies. Josamycin, a macrolide from an earlier generation, has rarely been studied for use in H. pylori infection. For these reasons, we tested these antibiotics with tripotassium dicitrato bismuthate to determine the ef®cacy of these non-metronidazole bismuth-based regimens at eradicating H. pylori.
In this study, we demonstrated that the combination of tripotassium dicitrato bismuthate, clarithromycin and furazolidone achieved the highest eradication rate (88% on intention-to-treat analysis and 93% on per protocol analysis) of the three bismuth-based triple therapies tested. The dosages of clarithromycin and furazolidone used in this regimen were relatively low, and the 1-week treatment course was relatively short. Moreover, the patients tolerated the regimen quite well. Therefore, this combination ful®ls the criteria for successful H. pylori therapy. In a previous pilot study of furazolidone-containing therapy for H. pylori infection, we demonstrated that primary resistance to clarithromycin is the key factor for treatment failure while using this regimen. 21 Compared to cure rates of 90% or more achieved by the triple therapies containing a proton pump inhibitor, clarithromycin and amoxycillin, the cure rate obtained by the replacement of proton pump inhibitor with tripotassium dicitrato bismuthate in our present study is relatively low (58% on intention-to treat analysis and 64% on per protocol analysis). Although clarithromycin is less dependent on acid suppression for its ef®cacy, amoxycillin is largely dependent upon this acid suppression. 22, 23 We speculate that the reduced ef®cacy of amoxycillin due to reduced acid suppression in our study may explain the relatively low cure rate observed with this regimen. Josamycin-combined therapy for H. pylori infection has rarely been reported. Although the combination of tripotassium dicitrato bismuthate, josamycin and furazolidone in this study achieved suboptimal results (77% on intention-to-treat analysis and 85% on perprotocol analysis), it is inexpensive, widely available and may be used as an alternative when clarithromycin is not available. We conclude that the 1-week low-dose triple therapy consisting of tripotassium dicitrato bismuthate, clarithromycin and furazolidone provides a satisfactory result for the cure of H. pylori infection, and may become an important alternative in the light of a worldwide increase in H. pylori resistance to metronidazole.
